Precision BioSciences, Inc. (DTIL) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Precision BioSciences, Inc. (DTIL) closed at USD 6.03 on 2026-10-14, a change of -27.3 % over the past year, with a market capitalization of USD 170.3M.
Precision BioSciences, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 6.03 |
| 2026-10-13 | 6.10 |
| 2026-10-12 | 6.53 |
| 2026-10-09 | 6.72 |
| 2026-10-08 | 6.43 |
| 2026-10-07 | 6.25 |
| 2026-10-06 | 6.20 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Precision BioSciences, Inc. key figures
- Previous close
- USD 6.03 (2026-10-14)
- 1-year change
- -27.3 %
- Market cap
- USD 170.3M
- Enterprise value
- USD 110.85M
- P/E ratio (trailing)
- -4.57
- P/E ratio (forward)
- -3.32
- EPS (trailing)
- -1.35
- EPS (forward)
- -1.86
- PEG ratio
- n/a
- Price to book
- 3.60
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 9.96
- Employees
- 67
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Precision BioSciences, Inc. and compare it with other stocks.
Analyze DTILAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Precision BioSciences, Inc. shares.